National Cancer Institute of Brazil, Rio de Janeiro, Brazil (INCA).
Clinical Research Division, National Cancer Institute of Brazil, Rio de Janeiro, Brazil (INCA).
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Oct;132(4):e143-e152. doi: 10.1016/j.oooo.2020.04.007. Epub 2020 May 31.
The aim of this systematic review was to describe the epidemiology, diagnostic criteria, differential diagnosis, treatment, prognostic factors, and treatment outcomes of secretory carcinoma.
A comprehensive search of Lilacs, PubMed, Science Direct, and Web of Science databases was conducted to identify all case reports, letter to the editor, and histopathologic reclassifications regarding salivary gland secretory carcinoma published in English, Spanish, French, and Portuguese.
The final analysis included 119 studies, which totaled 642 secretory carcinoma diagnoses, with 239 case reports and 403 diagnostic reclassifications, mostly in the United States. The age range was 5 to 87 years, and cases were predominantly in males (58.7%) and mostly affecting the parotid glands (73.7%). The disease usually presents as a slow-growing, painless mass. The main differential diagnosis is acinic cell carcinoma, and the tumor is usually treated with surgery. The prognosis is considered favorable, although there have been reports of local recurrences, distant metastases, and deaths.
It is important that clinicians become aware of this salivary gland neoplasm and report clinical data, clinical course, management and long-term follow-up. There is an urgent need to conduct more clinical trials, especially on tropomyosin receptor kinase (TRK) inhibitors and other potential target therapy modalities.
本系统评价旨在描述分泌性癌的流行病学、诊断标准、鉴别诊断、治疗、预后因素和治疗结果。
对 Lilacs、PubMed、Science Direct 和 Web of Science 数据库进行全面检索，以确定所有关于唾液腺分泌性癌的英文、西班牙语、法语和葡萄牙语病例报告、给编辑的信和组织病理学重新分类的文献。
最终分析包括 119 项研究，共计 642 例分泌性癌诊断，其中 239 例病例报告和 403 例诊断重新分类，主要来自美国。年龄范围为 5 至 87 岁，病例主要为男性（58.7%），主要影响腮腺（73.7%）。疾病通常表现为生长缓慢、无痛的肿块。主要的鉴别诊断是腺泡细胞癌，肿瘤通常通过手术治疗。预后被认为是良好的，尽管有局部复发、远处转移和死亡的报道。
临床医生需要了解这种唾液腺肿瘤，并报告临床数据、临床过程、管理和长期随访情况。迫切需要开展更多的临床试验，特别是关于原肌球蛋白受体激酶（TRK）抑制剂和其他潜在的靶向治疗方法。
